Neuronetics, Inc. STIM

Neuronetics Inc (STIM) reports 9.1% revenue growth and positive adjusted EBITDA, signaling a strong turnaround in Q2 2026.

Neuronetics improved margins, reached positive adjusted EBITDA and lowered its 2026 operating expense outlook, although NeuroStar revenue declined during the quarter. Key Investor TakeawaysNeuronetics (NASDAQ:STIM) reported second-quarter revenue of $41.

MALVERN, Pa., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced its financial and operating results for the second quarter of 2026. Second Quarter 2026 Financial Highlights Total revenue of $41.6 million, up 9.1% compared to the second quarter of 2025Gre

Chernett Affirms Comfort with the Company’s Capital Position and Confidence in Management’s ExecutionEstablishes Path Towards Neuronetics Board Representation MALVERN, Pa., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (“Neuronetics” or the “Company”) and Jorey Chernett, the Company’s second largest shareholder and Managing Member of Pointillist Family Office, today announced that they have created a constructive framework for alignment between the Company’s Board of Directo

MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced the granting of inducement awards to five new non-executive employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as a ma

New location expands access to advanced mental health treatments while serving as Greenbrook's flagship innovation center and blueprint for future care deliveryMALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced the grand opening of Greenbrook Mental Wellness Centers’ Nation

MALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced that it plans to release second quarter 2026 financial and operating results prior to market open on Tuesday, August 11, 2026. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same

Brainsway shares have rallied more than 60% this year, with more bullish tailwinds at its back.

Nir Naor appointed Chief Financial Officer effective July 23, 2026, bringing more than 20 years of finance and life sciences experienceCory Anderson promoted to Executive Vice President and General Manager, Greenbrook effective July 1, 2026Andrew Macan to step down as Executive Vice President, Chief Legal Officer & Corporate Secretary, effective August 15, 2026 MALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines

Neuronetics, Inc. (NASDAQ:STIM) is one of the 10 High Growth Stocks Insiders Are Buying. On July 6, 2026, Neuronetics, Inc. (NASDAQ:STIM) announced that management will participate at B. Riley Securities’ Mind, Muscle & Vision Summit, an invitation-only institutional investor event being held in person at the InterContinental Boston. Neuronetics will participate in a panel discussion titled […]